UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

~~WASHINGTON,~~FORM ~~D.C. 20549~~8-K

CURRENT REPORT

~~Pursuant~~PURSUANT toTO ~~Section~~SECTION 13 orOR 15(dD) ofOF ~~the~~THE

~~Securities~~SECURITIES ~~Exchange~~EXCHANGE ~~Act~~ACT ofOF 1934

~~Date~~June ~~of Report (Date of earliest event reported): March 31~~18, ~~2012~~2015

~~Emergent~~Date ~~Health~~of ~~Corp.~~Report (Date of earliest event reported)

EMERGENT HEALTH CORP.

(Exact name of registrant as specified in its charter)

Nevada


Nevada	000-54404	20-8944630
(State or other	(Commission File Number)	(IRS Employer
Jurisdiction of Incorporation)		Identification Number)

~~(State~~2424 orNorth ~~other~~Federal ~~jurisdiction of incorporation or organization)~~Highway

~~208944630~~Suite 257

~~(I.R.S.~~Boca ~~Employer~~Raton, ~~Identification Number)~~FL 33431

~~20104 VALLEY FORGE CIRCLE~~_________________________________________

~~KING~~(Address OFof ~~PRUSSIA~~Principal ~~19406~~Executive Offices (Zip Code)

~~(Address~~20104 ofValley ~~principal~~Forge ~~executive offices) (Zip Code)~~Circle

~~866-427-6143~~King of Prussia, PA

~~Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:~~19406

________________________________________________

(Former Address of Principal Executive Offices) (Zip Code)

(561) 961-4344

_________________________________________

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Section 5 -1- Corporate Governance and Management

~~Emergent~~Item ~~Health~~5.02 ~~Corp~~Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

~~Item~~Termination ~~8.01 Other Events- Management Discussion and Analysis~~ of ~~First~~John ~~Quarter 2012 Results Compared to First Quarter 2011~~Launie:

~~Emergent~~On ~~Health~~June ~~Corp.~~17, (2015 the ~~"Company")~~Board isof aDirectors ~~non-reporting~~terminated ~~public~~Mr. ~~company~~Launie’s employment ~~performing~~with athe ~~voluntary~~Company. Mr. ~~filing~~Launie onpreviously ~~this~~served ~~Current~~as ~~Report on Form 8-K (~~the ~~"Form~~Company’s ~~8-K")~~chief toexecutive ~~update~~officer, ~~the Management~~chief ~~Discussion~~financial ~~and~~officer ~~Analysis of Financial Condition~~ and ~~Results~~as ofa ~~Operations~~director ~~for the first quarter~~ of ~~2012 compared to~~ the ~~first quarter of 2011 for its private and public investors~~Company.

~~For~~Appointment ~~the first quarter~~ of ~~2012,~~Chris ~~unaudited~~Swenson ~~revenues~~as ~~for~~Chief ~~Jan.~~Executive ~~1 to Mar. 31~~Officer, ~~2012~~president are preliminarily estimated at approximately $494,509.80 compared to $70,837.61 for Jan. 1 to March 31 2011. This would be an up to 600% increase. The Company's sales for the first quarter preliminarily seem to exceed the entire first half of last year by an estimated $300,000.00. The Company attributes this to increased U.S.A. and International demand for multiple new products as well the successful launch of its new MultVitamin-MultiMineral with Stem Cell Nutrition and added Vitamin D. The Company is optimistic. However, there is no guarantee this volume or rate of increase will continue.director:

~~Net~~On ~~profit,~~June ~~(unaudited) before taxes for the period Jan. 1 to Mar. 31~~15, ~~2012,~~2015 ~~appears preliminarily to be approximately up to $189,195.17. This compares to $30,383.33 for~~ the ~~period~~Board ~~Jan~~of 1,Directors toelected ~~Mar.~~Chris ~~31,~~Swenson ~~2011. On a pretax per share basis this is $0.008 per share for the most recent quarter compared~~ to ~~$0.0013 per share to~~ the ~~comparable~~Company’s ~~quarter~~Board last year. This is an approximate up to 600% increase and attributed to added sales plus tight cost control. These margins could decrease as there may be an ongoing need to further increase staff in the future and there is no guarantee these rates of ~~increase will continue~~Directors.

~~The~~On ~~Company's~~June ~~total assets as of Mar. 31~~17, ~~2012~~2014 ~~were~~Mr ~~preliminarily~~Swenson ~~estimated~~was atalso ~~$1,200,000.00~~appointed ~~compared~~the toCompany’s $new ~~435,726.00~~chief asexecutive ofofficer ~~Mar.~~and 31president. ~~2011~~

~~The~~Mr. Swenson brings over 25 years of financial experience to the Company's. His ~~cash~~areas ~~position~~of ~~was~~concentration ~~preliminarily~~include ~~estimated~~financial atanalysis, $1strategic planning,~~121,002~~ business development and budgeting.00 Since 2014 Mr. Swenson has served as the Chief Financial Officer of Neaclear ~~Mar~~, Inc. ~~31,~~a ~~2012~~company ~~compared~~located toat ~~$405~~550 West Adams Street,~~556~~ Suite 900, Chicago, IL 60661 engaged in marketing and the distribution of Skin Care.00 From 2009 through 2013 he served as the Chief Financial Officer of ~~Mar~~CENX, Inc., 31located in Ottowa, ~~2011~~ON CANADA whose principal business was Software Services From 2001 through 2008 he served as the VP of Finance for Inteliquent Corp, located in Chicago, Il and engaged in Telecom Services.

~~The Company believes it is adequately funded for this year and moving forward~~Mr. ~~The~~Swenson ~~Company~~earned ~~expects~~his ~~to further introduce its Anti-Aging supplement this year, as well as other new products~~B. ~~Another 5000 bottle purchase of the Anti-Aging supplement did take place as anticipated last quarter~~A. ~~The~~from ~~Company continues to move forward on a beta networking launch that may make~~ the ~~Anti-Aging~~University ~~project~~of ~~more~~New ~~profitable~~Hampshire ~~than~~and ~~acting~~his ~~just~~MBA asfrom aBabson ~~vendor~~College. ~~The Company intends to retire a Convertible Preferred Stock outstanding to decrease potential dilution in the next quarter.~~

~~The~~In ~~above~~connection iswith ~~intended~~his asappointment ~~a “snapshot” overview. The term “preliminarily” is used~~ as the Company’s isnew ~~experiencing~~CEO aand ~~Quick~~president, ~~Books accounting integration issue~~Mr. ~~The~~Swenson ~~Company~~entered isinto ~~utilizing~~an ~~manually extracted correlations of cost accounting data from Quick Books~~Employment, ~~sales~~Non-Compete ~~revenue figures from selling software~~ and ~~then~~Proprietary ~~performing~~Rights ~~actual~~Agreement ~~bank statement comparisons. This leads to figures~~ (the ~~Company~~“Agreement”) The ~~believes~~Agreement ~~are realistic estimates until the integration issue~~ is ~~resolved. Exhibits related to unaudited Balance Sheet and Operating Statement~~ for ~~2012 periods are intended at~~ a ~~later~~term ~~date~~of ~~after~~three ~~further review~~years.

~~This~~Base voluntary filing contains certain "forward-looking" statements, defined in the United States Private Securities Litigation Reform Act of 1995, that involve a number of risks and uncertainties. Statements, which are not historical facts, are forward-looking statements. The Company, through its management, makes forward-looking public statements concerning its expected future operations, performance and other developments. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. It is impossible to identify all such factors that could cause actual results to differ materially from those estimated by the Company.Salary:

~~-2-~~The Agreement provides for a base salary of $275,000.00 per annum, subject to increase in the sole discretion of the Board of Directors of the Company.

~~SIGNATURES~~Common Stock Option Grants:

~~Pursuant~~The Company has issued 1,000,000 common stock options. The options are for a period of ten years, vest immediately at an exercise price of $100,000 in total ($0.10 per share with no increase in purchase price for anti-dilution rights). Based upon the Company’s then capitalization of approximately 41,930,000 shares before giving effect to this represents approximately 2.33% of the ~~requirements~~Company fully diluted before giving effect to the grant of executive stock options. These stock option will have anti-dilutions rights so that after giving effect to these options and the ~~Securities~~issuances ~~Exchange~~of ~~Act~~capital stock and options through the placement of ~~1934~~the first $3,000,000 in additional equity of the ~~Registrant~~Company, ~~has~~Mr. ~~duly~~Swenson ~~caused~~will ~~this~~hold ~~report~~common stock options to bepurchase ~~signed~~up onto ~~its~~2.33% ~~behalf~~of bythe Company (fully diluted) per the ~~undersigned~~common ~~hereunto~~stock ~~duly~~options ~~authorized~~and up to 5% of the Company (fully diluted) inclusive of the executive stock option grant below..

	Emergent Health Corp.
Date: June 4, 2012	By:	/s/ John V. Cappello
		John V. Cappello
		CEO, Chief Financial Officer

Executive Stock Option Grants:

-Mr. Swenson has been granted executive stock options with an exercise price of $226,233 in the aggregate to purchase an amount equal to 5% of the fully diluted capitalization of the Company (inclusive of the common stock options) after giving effect to the issuances of the next $3-,000,000 in equity capital raised by the Company, as well as any new stock options granted through the date of closing upon such equity. These options will vest monthly over three years and will fully vest upon change in change in control.

Bonus:

Mr. Swenson will earn an annual bonus of $150,000 upon aggregate fresh capital raised of $2,500,000 by the Company following the date of this Agreement.

- 2 -

Benefits:

Mr. Swenson will receive offered health benefits for himself and his family, at no additional cost, in an amount not less than the greatest level of coverage offered to other employees in the Company.

You are urged to review the employment agreement in its entirety which is attached hereto as Exhibit 10.1.

Section 9 - Financial Statements and Exhibits


Exhibit No.		Description

Exhibit 10.1		Employment Agreement

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	EMERGENT HEALTH CORP.

Date: September 18, 2015	By: /s/ Chris Swenson
	Chris Swenson
	CEO/President

- 3 -

Filing Compare · Emergent Health Corp.